Pembrolizumab improves os across pd-l1 subgroups


Pembrolizumab improves os across pd-l1 subgroups

Play all audios:


Access through your institution Buy or subscribe In 2016, KEYNOTE-024 established the superior efficacy of first-line pembrolizumab over chemotherapy for metastatic non-small-cell lung


cancer (NSCLC) with a programmed cell death 1 ligand 1 (PD-L1) tumour proportion score (TPS) ≥50%. Now, overall survival (OS) data from the second interim analysis of KEYNOTE-042, which


investigated the efficacy of pembrolizumab in patients with a lower PD-L1 TPS, have been reported. The phase III trial enrolled 1,274 patients with previously untreated, PD-L1-positive (TPS


≥1%), locally advanced or metastatic NSCLC without a sensitizing _EGFR_ or _ALK_ alteration. Patients were randomized 1:1 to receive pembrolizumab or platinum-based chemotherapy. The primary


end point was OS across three predefined subgroups (TPS ≥50%, ≥20% and ≥1%). This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your


institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal


Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices


may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support


REFERENCES ORIGINAL ARTICLE * Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer


(KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. _Lancet_. https://doi.org/10.1016/S0140-6736(18)32409-7 (2019) Article  PubMed  Google Scholar  Download references AUTHOR


INFORMATION AUTHORS AND AFFILIATIONS * Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc Conor A. Bradley Authors * Conor A. Bradley View author publications You can also


search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Conor A. Bradley. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE


Bradley, C.A. Pembrolizumab improves OS across PD-L1 subgroups. _Nat Rev Clin Oncol_ 16, 403 (2019). https://doi.org/10.1038/s41571-019-0213-5 Download citation * Published: 16 April 2019 *


Issue Date: July 2019 * DOI: https://doi.org/10.1038/s41571-019-0213-5 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link


Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative